Clinical trial
A Phase 1, Single and Multiple Ascending Dose and Food Effect Study of NEU-411 Administered Orally to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Healthy Subjects
NCT05755191 is registered in ClinicalTrials.gov with Neuron23 Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Single and Multiple Ascending Dose and Food Effect Study of NEU-411 Administered Orally to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Healthy Subjects
- Lead sponsor
- Neuron23 Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- May 13, 2023
- Completion date
- June 3, 2024
- Enrollment
- 147 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
healthy